Test ID: CAH21
Congenital Adrenal Hyperplasia (CAH) Profile for 21-Hydroxylase Deficiency
Secondary ID
A test code used for billing and in test definitions created prior to November 2011
NY State Approved
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For
Suggests clinical disorders or settings where the test may be helpful
Preferred screening test for congenital adrenal hyperplasia (CAH) that is caused by 21-hydroxylase deficiency
Part of a battery of tests to evaluate females with hirsutism or infertility, which can result from adult-onset CAH
Genetics Test Information
Provides information that may help with selection of the correct test or proper submission of the test request
Preferred screening test for congenital adrenal hyperplasia (CAH) that is caused by 21-hydroxylase deficiency. Also useful as part of a battery of tests to evaluate females with hirsutism or infertility, which can result from adult-onset CAH.
Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| CORTI | Cortisol, S | Yes, (order CINP) | Yes |
| ANDRO | Androstenedione, S | Yes, (order ANST) | Yes |
| H17 | 17-Hydroxyprogesterone, S | Yes, (order OHPG) | Yes |
Method Name
A short description of the method used to perform the test
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases
Lists additional common names for a test, as an aid in searching
21 Hydroxylase Deficiency
Androstenedione
CA21H
CAH (Congenital Adrenal hyperplasia)
Corticosteroids
Cortisol
CYP21
Delta-4-Androstenedione
17-Alpha Hydroxyprogesterone (17-OHP)
Progesterone, 17-Alpha Hydroxy
Specimen Type
Describes the specimen type needed for testing
Specimen Required
Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Container/Tube: Red top
Specimen Volume: 0.6 mL
Collection Instructions:
1. Morning (8 a.m.) and afternoon (4 p.m.) specimens are preferred.
2. Include time of draw.
Additional Information: If multiple specimens are drawn, send separate order for each specimen.
Specimen Minimum Volume
Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | Mild OK; Gross reject |
| Lipemia | Mild OK; Gross reject |
| Icterus | Mild OK; Gross OK |
| Other | Serum gel tube |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum Red | Refrigerated (preferred) | 7 days |
| Frozen | 14 days |
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The cause of congenital adrenal hyperplasia (CAH) is an inherited genetic defect that results in decreased formation of 1 of the many enzymes that are involved in the production of cortisol. The enzyme defect results in reduced glucocorticoids and mineralocorticoids, and elevated 17-hydroxyprogesterone (OHPG) and androgens. The resulting hormone imbalances can lead to life-threatening, salt-wasting crises in the newborn period and incorrect gender assignment of virilized females. Adult-onset CAH may result in hirsutism or infertility in females.
The adrenal glands, ovaries, testes, and placenta produce OHPG. It is hydroxylated at the 11 and 21 positions to produce cortisol. Deficiency of either 11- or 21-hydroxylase results in decreased cortisol synthesis, and the feedback inhibition of adrenocorticotropic hormone (ACTH) secretion is lost. Consequently, increased pituitary release of ACTH increases production of OHPG. In contrast, if 17-alpha-hydroxylase (which allows formation of OHPG from progesterone) or 3-beta-ol-dehydrogenase (which allows formation of 17-hydroxyprogesterone formation from 17-hydroxypregnenolone) are deficient, OHPG levels are low with possible increase in progesterone or pregnenolone, respectively.
Most (90%) cases of CAH are due to mutations in the 21-hydroxylase gene (CYP21A2). CAH due to 21-hydroxylase deficiency is diagnosed by confirming elevations of OHPG and androstenedione with decreased cortisol. By contrast, in 2 less common forms of CAH, due to 17-hydroxylase or 11-hydroxylase deficiency, OHPG and androstenedione levels are not significantly elevated and measurement of progesterone (PGSN/8141 Progesterone, Serum) and deoxycorticosterone (DCRN/8847 11-Deoxycorticosterone, Serum), respectively, are necessary for diagnosis.
OHPG is bound to both transcortin and albumin, and total OHPG is measured in this assay. OHPG is converted to pregnanetriol, which is conjugated and excreted in the urine. In all instances, more specific tests than pregnanetriol measurement are available to diagnose disorders of steroid metabolism.
The CAH profile allows the simultaneous determination of OHPG, androstenedione, and cortisol. These steroids can also be ordered individually (OHPG/9231 17-Hydroxyprogesterone, Serum; ANST/9709 Androstenedione, Serum; CINP/9369 Cortisol, Serum, LC-MS/MS).
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
CORTISOL
5-25 mcg/dL (a.m.)
2-14 mcg/dL (p.m.)
Pediatric reference ranges are the same as adults, as confirmed by peer-reviewed literature.
Petersen KE: ACTH in normal children and children with pituitary and adrenal diseases. I. Measurement in plasma by radioimmunoassay-basal values. Acta Paediatr Scand 1981;70:341-345
ANDROSTENEDIONE
PEDIATRICS*
Premature infants
26-28 weeks, day 4: 92-282 ng/dL
31-35 weeks, day 4: 80-446 ng/dL
Full-term infants
1-7 days: 20-290 ng/dL
1 month-1 year: <69 ng/dL
Males*
| Tanner Stages | Age (Years) | Reference Range (ng/dL) |
| Stage I (prepubertal) | <9.8 | <51 |
| Stage II | 9.8-14.5 | 31-65 |
| Stage III | 10.7-15.4 | 50-100 |
| Stage IV | 11.8-16.2 | 48-140 |
| Stage V | 12.8-17.3 | 65-210 |
Females*
| Tanner Stages | Age (Years) | Reference Range (ng/dL) |
| Stage I (prepubertal) | <9.2 | <51 |
| Stage II | 9.2-13.7 | 42-100 |
| Stage III | 10.0-14.4 | 80-190 |
| Stage IV | 10.7-15.6 | 77-225 |
| Stage V | 11.8-18.6 | 80-240 |
*Source: Androstenedione. In Pediatric Reference Ranges. Fourth Edition. Edited by SJ Soldin, C Brugnara, EC Wong. Washington, DC, AACC Press, 2003, pp 32-34
ADULTS
Males: 40-150 ng/dL
Females: 30-200 ng/dL
17-HYDROXYPROGESTERONE
Children
Preterm infants: Preterm infants may exceed 630 ng/dL, however, it is uncommon to see levels reach 1,000 ng/dL.
Term infants
0-28 days: <630 ng/dL
Levels fall from newborn (<630 ng/dL) to prepubertal gradually within 6 months.
Prepubertal males: <110 ng/dL
Prepubertal females: <100 ng/dL
Adults
Males: <220 ng/dL
Females
Follicular: <80 ng/dL
Luteal: <285 ng/dL
Postmenopausal: <51 ng/dL
Note: For pregnancy reference ranges, see: Soldin OP, Guo T, Weiderpass E, et al: Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril 2005 Sept;84(3):701-710
Interpretation
Provides information to assist in interpretation of the test results
Diagnosis and differential diagnosis of congenital adrenal hyperplasia (CAH) always requires the measurement of several steroids. Patients with CAH due to 21-hydroxylase gene (CYP21A2) mutations usually have very high levels of androstenedione, often 5- to 10-fold elevations. 17-Hydroxyprogesterone (OHPG) levels are usually even higher, while cortisol levels are low or undetectable. All 3 analytes should be tested.
In the much less common CYP11A mutation, androstenedione levels are elevated to a similar extent as in CYP21A2 mutation, and cortisol is also low, but OHPG is only mildly, if at all, elevated.
Also less common is 3 beta-hydroxysteroid dehydrogenase type 2 (3 beta HSD-2) deficiency, characterized by low cortisol and substantial elevations in dehydroepiandrosterone sulfate (DHEA-S) and 17-alpha-hydroxypregnenolone, while androstenedione is either low, normal, or rarely, very mildly elevated (as a consequence of peripheral tissue androstenedione production by 3 beta HSD-1).
In the very rare STAR (steroidogenic acute regulatory protein) deficiency, all steroid hormone levels are low and cholesterol is elevated.
In the also very rare 17-alpha-hydroxylase deficiency, androstenedione, all other androgen-precursors (17-alpha-hydroxypregnenolone, OHPG, DHEA-S), androgens (testosterone, estrone, estradiol), and cortisol are low, while production of mineral corticoid and its precursors, in particular progesterone, 11-deoxycorticosterone, corticosterone, and 18-hydroxycorticosterone, are increased.
The goal of CAH treatment is normalization of cortisol levels and, ideally, also of sex-steroid levels. OHPG is measured to guide treatment, but this test correlates only modestly with androgen levels. Therefore, androstenedione and testosterone should also be measured and used to guide treatment modifications. Normal prepubertal levels may be difficult to achieve, but if testosterone levels are within the reference range, androstenedione levels up to 100 ng/dL are usually regarded as acceptable.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Androstenedione and, to a lesser degree, dehydroepiandrosterone sulfate supplements can result in elevations of serum androstenedione level. With large androstenedione doses of 300 to 400 mg/day, serum androstenedione levels can almost double in some patients. Testosterone levels and, particularly in men, estrone and estradiol levels may also increase, but to a much lesser degree.
This test provides merely supplementary information and should, therefore, never be employed as the sole diagnostic tool.
Clinical Reference
Provides recommendations for further in-depth reading of a clinical nature
1. Von Schnakenburg K, Bidlingmaier F, Knorr D: 17-hydroxyprogesterone, androstenedione, and testosterone in normal children and in prepubertal patients with congenital adrenal hyperplasia. Eur J Pediatr 1980;133(3):259-267
2. Sciarra F, Tosti-Croce C, Toscano V: Androgen-secreting adrenal tumors. Minerva Endocrinol 1995;20(1):63-68
3. Collett-Solberg PF: Congenital adrenal hyperplasia: from genetics and biochemistry to clinical practice, part I. Clin Pediatr 2001;40(1):1-16
4. Speiser PW, Azziz R, Baskin LS, et al: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010;95(9):4133-4160; Available at URL: jcem.endojournals.org
Method Description
Describes how the test is performed and provides a method-specific reference
Deuterated stable isotopes (d4-cortisol, d7-androstenedione, d8-17-hydroxyprogesterone) are added to a 0.1-mL serum sample as internal standards. Cortisol, androstenedione, 17-hydroxyprogesterone, and the internal standards are extracted from specimens using a Strata X 30-mg cartridge and eluted from the cartridge with methanol. The extracts are then dried down under nitrogen, reconstituted with 75 mcL of 70/30 methanol/H2O containing 1 g/mL of estriol and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using multiple-reaction monitoring. A calibration curve is generated by spiking standards into a bovine serum albumin (BSA) buffer and extracted with each batch of new working internal standard. Controls are extracted with each batch.(Unpublished Mayo method)
Day(s) and Time(s) Test Performed
Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; 2 p.m.
Analytic Time
Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time
Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location
The location of the laboratory that performs the test
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
82157-Androstenedione
82533-Cortisol; total
83498-Hydroxyprogesterone, 17-d
LOINC® Code Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 30041 | Androstenedione, S | 1854-9 |
| 30042 | 17-Hydroxyprogesterone, S | 1668-3 |
| 30040 | Cortisol, S | 2143-6 |
| 30070 | AM Cortisol | 9813-7 |
| 30071 | PM Cortisol | 9812-9 |


